Product – Export – Generics
Generics formulation marks a new chapter in the growth story of Concord. We have forward integrated from API’s to Formulations and have successfully submitted ANDA’s in the regulated markets and plan to take our dossiers for global filings. Concord has a robust pipeline of niche formulation dossiers under development, which it intends to commercialize in coming years.
The ANDAs filings are targeted in therapeutic segments of Immunosuppressants and the Oncology with focus on Solid oral dosages (tablets & capsules), Oral Solution and Oral suspensions.
We are also exploring opportunities to collaborate with Companies across geographies through various business models of out-licensing, co-marketing and by establishing global business distribution network in order to provide high quality and bio-equivalent finished products to patients globally.